Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Docetaxel (Taxotere) - an update.

H Lacroix1, C Ligeza

  • 1Service d'Oncologie Médicale Hôtel-Dieu, Centre Hospitalier Universitaire, 44093 Nantes, Cédex 1, France.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary

Docetaxel, a taxoid chemotherapy, shows high response rates in breast cancer and non-small-cell lung cancer (NSCLC) monotherapy. While neutropenia is a dose-limiting toxicity, its efficacy in advanced cancers is promising.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cementless versus cemented Oxford unicompartmental knee arthroplasty: early results of a non-designer user group.

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA·2016
Same author

Revision from unicompartmental to total knee replacement: the clinical outcome depends on reason for revision.

The bone & joint journal·2013
Same author

[Sarcomas management network in France].

Bulletin du cancer·2010
Same author

Treatment of scaphoid non-union with a percutaneous corticocancellous bone graft.

Journal of hand surgery (Edinburgh, Scotland)·2005
Same author

[Isolated and asymptomatic Brugada syndrome. A case report].

Annales de cardiologie et d'angeiologie·2002
Same author

Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis.

Cancer gene therapy·2001

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Research

Background:

  • Docetaxel is a rapidly developed taxoid chemotherapy agent.
  • Phase I studies established a recommended dose of 100 mg/m(2) every three weeks, with neutropenia as the primary dose-limiting toxicity.

Purpose of the Study:

  • To review the efficacy and safety of docetaxel in major clinical trials.
  • To assess docetaxel's role in treating breast cancer, non-small-cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and gastric cancer.

Main Methods:

  • Review of Phase I, II, and III clinical studies.
  • Analysis of response rates and toxicities in various cancer types.

Main Results:

  • In advanced NSCLC, Phase II studies reported 30-40% response rates, including in cisplatin-refractory cases.
  • For advanced breast cancer, first-line treatment showed 54-68% response rates with minimal cross-resistance in second-line therapy.
  • Encouraging response rates (around 40%) were observed in SCCHN, with ongoing combination studies showing promise.

Conclusions:

  • Docetaxel demonstrates high response rates as monotherapy in NSCLC and breast cancer.
  • Further long-term data are needed to define its role in combination therapies.
  • Docetaxel is a promising chemotherapeutic agent with significant efficacy in several advanced cancers.

Related Experiment Videos